This guidance advises those involved in clinical trials on specific issues which may arise as a result of COVID-19, and what they are required to do.
We have separate guidance on Clinical trials applications for Coronavirus (COVID-19).
The MHRA will be as flexible and pragmatic as possible with regard to regulatory requirements for clinical trials during this time. We recognise that clinical trial resource may be absent or redeployed from research activities and regulatory affairs towards front-line care.
The first priority should be the safety of trial participants and this will remain our focus.
This guidance will be updated as the situation changes over time.